Study #2021-0953
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Venetoclax
MD Anderson Study Status
Not Accepting
Treatment Agent
Pirtobrutinib, Venetoclax
Description
To learn if the combination of LOXO-305 (pirtobrutinib) and venetoclax can help to control previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study phase:
Phase II
Physician name:
Alessandra Ferrajoli
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.